文献速递临床试验与 GCP基础与转化研究

粒细胞集落刺激因子在激素部分或无应答的重度酒精性肝炎患者中的疗效(GRACIAH试验):随机对照试验研究方案

Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-12-22

本研究为随机对照试验方案,旨在评估粒细胞集落刺激因子(G-CSF)能否提高对糖皮质激素无应答的重度酒精性肝炎患者的短期生存率。筛选MDF评分≥32且接受泼尼松龙40 mg/天治疗1周的患者,根据Lille评分分为部分应答(PR,0.16-0.56)和无应答(NR,≥0.56)两组。PR组随机接受激素加安慰剂或激素加12次G-CSF注射,NR组随机接受安慰剂或G-CSF。主要终点NR组为2个月生存率,PR组为6个月生存率。

要点

  • G-CSF可能延长激素难治性重度酒精性肝炎患者的短期生存。
  • Lille评分指导分层:部分应答者用激素联合G-CSF,无应答者单用G-CSF或安慰剂。
  • 主要终点:无应答组2个月生存率,部分应答组6个月生存率。

核心结论

  • 假设G-CSF可延长对糖皮质激素无应答的重度酒精性肝炎患者的短期生存。
  • 本试验为概念验证性试验,旨在评估Lille评分指导的G-CSF治疗疗效,并识别G-CSF补救治疗可改善肝功能并延长生存的亚组。

研究设计与样本

  • 随机对照试验方案,计划纳入190例部分应答(Lille评分0.16-0.56)和78例无应答(Lille评分≥0.56)的重度酒精性肝炎患者。
  • 筛选标准:MDF评分≥32且接受泼尼松龙40 mg/天治疗1周。
  • 部分应答组按1:1随机分配至激素加安慰剂或激素加12次G-CSF注射(5 μg/kg/天连续5天,之后每3天一次)。
  • 无应答组按1:1随机分配至安慰剂或G-CSF组。
  • 部分应答组泼尼松龙治疗28天后逐渐减量2周。

关键数值与推荐

  • 主要终点:无应答组2个月生存率,部分应答组6个月生存率。
  • 分析Child-Turcotte-Pugh评分、终末期肝病模型评分及外周循环CD34阳性细胞比例变化作为死亡风险因素。
  • 对部分应答研究前10例受试者进行初步安全性评估,依据国家骨髓捐赠计划G-CSF动员外周血干细胞供者评估方案决定是否继续。

临床怎么用

  • 对于MDF评分≥32的重度酒精性肝炎患者,接受泼尼松龙40 mg/天治疗1周后计算Lille评分以分层。
  • 部分应答者(Lille评分0.16-0.56)可考虑激素联合G-CSF治疗。
  • 无应答者(Lille评分≥0.56)可考虑G-CSF治疗。
  • 需监测Child-Turcotte-Pugh评分、MELD评分及外周血CD34阳性细胞比例变化。

局限性

  • 本方案为研究设计,尚未报告疗效和安全性结果。
  • 初步安全性数据仅基于部分应答研究前10例受试者。
  • 研究结论需待试验完成后确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alcoholic hepatitis (AH) has the most severe presentation among alcohol-related liver diseases. Corticosteroids are the most widely recommended treatment for severe AH. However, more innovative, refined treatment measures are required because of its high mortality despite corticosteroid treatment. This study aims to determine whether granulocyte colony stimulating factor (G-CSF) treatment increases short-term survival in patients with severe AH refractory to corticosteroid treatment. METHODS/DESIGN: Patients with severe AH whose Maddrey's discriminant function (MDF) score is ≥ 32 and who will be treated with prednisolone (40 mg/day) for 1 week will be screened. Among them, 190 subjects with a partial response (PR) (Lille score 0.16-0.56), and 78 subjects with a null response (NR) (Lille score ≥ 0.56) will be enrolled. Subjects with PR will be randomized to steroid plus placebo or steroid plus 12 G-CSF injections (5 μg/kg/day for 5 days followed by every 3 days) at a ratio of 1:1. Subjects with a NR will be randomized to the placebo or G-CSF group (1:1). Study subjects in the PR group will be treated with prednisolone for 28 days followed by dose tapering for an additional 2 weeks. The primary endpoint is the 2-month survival rate in the NR group and the 6-month survival rate in the PR group. Child-Turcotte-Pugh, model for end-stage liver disease score, and the change in the proportion of peripheral circulating CD34-positive cells will be analyzed as risk factors for mortality. Preliminary safety data for the initial 10 study subjects enrolled in the PR study will be assessed to determine whether the PR study would be continued, according to the G-CSF-mobilized, peripheral-blood stem cell donor assessment protocol of the National Marrow Donor Program. DISCUSSION: We hypothesized that G-CSF would prolong short-term survival of patients with severe AH refractory to corticosteroid treatment. This is a proof-of-concept trial designed to assess the efficacy of Lille-score-guided G-CSF treatment. This trial is also designed to identify a special subgroup in whom G-CSF rescue treatment would improve liver function and prolong survival. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02442180 . Prospectively registered on 13 May 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Cho Y, Park YS, Kim HY, et al. Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial. Trials. 2018. PMID: 30577864. doi:10.1186/s13063-018-3092-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。